Please ensure Javascript is enabled for purposes of website accessibility

Why Editas Medicine Stock Is Jumping 13.9% This Week

By Keith Speights - Jun 25, 2021 at 6:01AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company received a go-ahead to enroll kids in a study of its lead gene-editing candidate.

What happened

Shares of Editas Medicine (EDIT -1.65%) were up 13.9% this week as of the market close on Thursday. Most of this big gain came after a key announcement from the company on Wednesday about its phase 1/2 clinical study evaluating EDIT-101.

Editas said that an Independent Data Monitoring Committee (IDMC) gave a thumbs-up to enroll children with the rare genetic eye disorder Leber congenital amaurosis 10 (LCA10) in two pediatric cohorts of the study. 

So what

It's not surprising that the biotech stock spiked after the news. The IDMC endorsement is huge in that it appears to confirm an encouraging safety profile for EDIT-101, the company's lead pipeline candidate. If there were any serious reservations about the safety of the experimental gene-editing therapy, the IDMC wouldn't have cleared the way for children to be included in Editas' clinical trial.

DNA strands with a doctor in the background.

Image source: Getty Images.

Editas also had more good news to report. The company said that it has completed the dosing of patients in the adult mid-dose cohort of the clinical study of EDIT-101. It plans to move forward with the pediatric mid-dose cohort and adult high-dose cohort at the same time.

Now what

Editas expects to report initial data from its phase 1/2 study of EDIT-101 in September. The company plans to begin dosing patients in its pediatric mid-dose and adult high-dose cohorts of the study this summer. 

Keith Speights owns shares of Editas Medicine. The Motley Fool owns shares of and recommends Editas Medicine. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Editas Medicine, Inc. Stock Quote
Editas Medicine, Inc.
EDIT
$18.46 (-1.65%) $0.31

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.